We are live on ! Find out more
FCMI

Foresite Capital Management IV Portfolio holdings

AUM $237M
1-Year Est. Return 107.53%
This Fund
S&P 500
This Quarter Est. Return
+9.11%
1 Year Est. Return
+107.53%
3 Year Est. Return
+149.4%
5 Year Est. Return
+13.8%
10 Year Est. Return
–
AUM
$124M
AUM Growth
+$12.7M
Cap. Flow
+$3.41M
Cap. Flow %
2.76%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
–
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$5.22M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$1.81M
2
LYEL icon
Lyell Immunopharma
LYEL
+$9

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
1
Pharvaris
PHVS
$2.39B
$77.6M 62.7%
4,410,581
– –
MAZE
2
Maze Therapeutics
MAZE
$1.53B
$25.9M 20.93%
2,111,919
– –
LYEL icon
3
Lyell Immunopharma
LYEL
$309M
$7.08M 5.72%
800,399
-1
-0% -$9
XENE icon
4
Xenon Pharmaceuticals
XENE
$6.32B
$5.01M 4.05%
+160,000
New +$5.22M
KURA icon
5
Kura Oncology
KURA
$922M
$4.71M 3.81%
816,882
-295,000
-27% -$1.81M
RLAY icon
6
Relay Therapeutics
RLAY
$4.02B
$3.46M 2.79%
1,000,000
– –

Similar funds

BCM
Birmingham Capital Management Birmingham, Alabama $237M AUM 32.7% 1-Year Est. Return
ICMM
Integrated Capital Management (Michigan) Bloomfield, Michigan $237M AUM 23.03% 1-Year Est. Return
AG
ASO Group Road Town $237M AUM
FL
FreeGulliver LLC New Orleans, Louisiana $237M AUM 21.92% 1-Year Est. Return
TS
TradeWell Securities Fort Wayne, Indiana $237M AUM 24.02% 1-Year Est. Return
EA
Evolution Advisers Richmond, Virginia $237M AUM 12.93% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
MFA
Millington Financial Advisors Naperville, Illinois $237M AUM 22.22% 1-Year Est. Return

Foresite Capital Management IV's Q2 2025 Portfolio in Review

As of Q2 2025, Foresite Capital Management IV held 6 positions worth $124M, up 11% from $111M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management IV's Q2 2025 filing shows 1 new and 2 reduced positions. Its largest new stake was Xenon Pharmaceuticals: 160,000 shares worth $5.01M. The largest sale was Kura Oncology, an estimated $1.81M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Foresite Capital Management IV's largest Q2 2025 buy was Xenon Pharmaceuticals: 160,000 shares worth $5.01M.
  • Foresite Capital Management IV's biggest Q2 2025 reduction was Kura Oncology, cutting an estimated $1.81M.
  • Foresite Capital Management IV's ten largest holdings make up 100% of its $124M portfolio in Q2 2025.
  • Foresite Capital Management IV opened 1 new position and closed 0 in Q2 2025.
  • Foresite Capital Management IV's portfolio value rose 11% quarter-over-quarter to $124M.

Based on Foresite Capital Management IV's 13F filing for Q2 2025, filed 12 Aug 2025.